Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide.
No risks detected for TUB from our risk checks.
Proven track record and fair value.
Share Price & News
How has Financière de Tubize's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TUB has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: TUB exceeded the Belgian Pharmaceuticals industry which returned 7.7% over the past year.
Return vs Market: TUB exceeded the Belgian Market which returned -20.1% over the past year.
Price Volatility Vs. Market
How volatile is Financière de Tubize's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall StWhat Percentage Of Financière de Tubize SA (EBR:TUB) Shares Do Insiders Own?
1 year ago | Simply Wall StIf You Had Bought Financière de Tubize (EBR:TUB) Shares Three Years Ago You'd Have Made 11%
1 year ago | Simply Wall StWith A Return On Equity Of 12%, Has Financière de Tubize SA's (EBR:TUB) Management Done Well?
Is Financière de Tubize undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: TUB (€78.3) is trading above our estimate of fair value (€10.88)
Significantly Below Fair Value: TUB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TUB is good value based on its PE Ratio (13.1x) compared to the XE Pharmaceuticals industry average (22.2x).
PE vs Market: TUB is good value based on its PE Ratio (13.1x) compared to the Belgian market (13.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TUB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TUB is good value based on its PB Ratio (1.3x) compared to the BE Pharmaceuticals industry average (3.1x).
How is Financière de Tubize forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Financière de Tubize has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Financière de Tubize is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Financière de Tubize competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Financière de Tubize performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TUB has high quality earnings.
Growing Profit Margin: Insufficient data to determine if TUB's profit margins have improved over the past year.
Past Earnings Growth Analysis
Earnings Trend: TUB's earnings have grown by 10.1% per year over the past 5 years.
Accelerating Growth: TUB's earnings growth over the past year (13.2%) exceeds its 5-year average (10.1% per year).
Earnings vs Industry: TUB earnings growth over the past year (13.2%) exceeded the Pharmaceuticals industry 11.2%.
Return on Equity
High ROE: TUB's Return on Equity (9.8%) is considered low.
How is Financière de Tubize's financial position?
Financial Position Analysis
Short Term Liabilities: TUB's short term assets (€1.8M) do not cover its short term liabilities (€32.8M).
Long Term Liabilities: TUB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: TUB's debt to equity ratio (1.2%) is considered satisfactory.
Reducing Debt: TUB's debt to equity ratio has reduced from 8.6% to 1.2% over the past 5 years.
Debt Coverage: TUB's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if TUB's interest payments on its debt are well covered by EBIT.
What is Financière de Tubize current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TUB's dividend (0.79%) isn’t notable compared to the bottom 25% of dividend payers in the Belgian market (2.51%).
High Dividend: TUB's dividend (0.79%) is low compared to the top 25% of dividend payers in the Belgian market (5.33%).
Stability and Growth of Payments
Stable Dividend: TUB is not paying a notable dividend for the Belgian market, therefore no need to check if payments are stable.
Growing Dividend: TUB is not paying a notable dividend for the Belgian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: TUB is not paying a notable dividend for the Belgian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TUB's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Financière de Tubize has no CEO, or we have no data on them.
|President & Chairman of the Board||0.33yr||€7.00k||no data|
|Honorary Chairman||no data||no data||13.21% |
|Independent Director||1.33yrs||€7.00k||no data|
|Member of the Board of Directors||9.33yrs||€4.00k||no data|
|Independent Director||0.33yr||no data||no data|
Experienced Board: TUB's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Financière de Tubize SA's company bio, employee growth, exchange listings and data sources
- Name: Financière de Tubize SA
- Ticker: TUB
- Exchange: ENXTBR
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €3.485b
- Shares outstanding: 44.51m
- Website: https://www.financiere-tubize.be
- Financière de Tubize SA
- Allee de la Recherche 60
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TUB||ENXTBR (Euronext Brussels)||Yes||Bearer Shares||BE||EUR||Jan 1992|
|0D53||LSE (London Stock Exchange)||Yes||Bearer Shares||GB||EUR||Jan 1992|
|FTD||DB (Deutsche Boerse AG)||Yes||Bearer Shares||DE||EUR||Jan 1992|
|TUBB||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Bearer Shares||GB||EUR||Jan 1992|
|FTD||BST (Boerse-Stuttgart)||Yes||Bearer Shares||DE||EUR||Jan 1992|
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immuno ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/15 04:59|
|End of Day Share Price||2020/08/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.